Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Médica de Risaralda
Print version ISSN 0122-0667
Abstract
RIVERA TOQUICA, Alex; ALVAREZ VERA, Tatiana and OCHOA JARAMILLO, Francisco. Glycosylated hemoglobin behavior and frequency of hypoglycemia in type 2 diabetics treated with insulin glargine or NPH. Revista médica Risaralda [online]. 2015, vol.21, n.2, pp.3-10. ISSN 0122-0667.
To evaluate performance of glycosylated hemoglobin (HbAlc) and frequency of symptomatic hypoglycemia scheme with basal insulin glargine compared to NPH insulin in type 2 diabetics (DM2), served in a program of cardiovascular risk. Materials and methods: Observational retrospective cohort. 613 medical records of patients with DM2 managed scheme with basal insulin NPH or glargine, of which 76 met the inclusion criteria were reviewed. medical records were reviewed at the time of inclusion (see No. 1), six (see No. 2) and twelve months (see No. 3). Results: 13 patients in the glargine group and 63 in the NPH group (age 64.9 [± 10.9 years], 54% female) were analyzed. The consultation No. 1 mean HbA1c was 7.8% with NPH group and 7.5% in glargine group. At follow-up HbA1c levels were 7.5% in NPH group and 7.9% in glargine group (p = 0.4). Hypoglycemic events were 3 in the first visit and 4 in the third, all received NPH. In the second consultation five events occurred in patients with NPH and 1 case with glargine (p = 0.9). The variables most strongly associated with low levels of HbA1c were chronic kidney disease and women. Conclusions: Patients with DM2 of this study showed no statistically significant difference in HbA1c values according to the type of insulin received. Lower frequency of hypoglycemia in patients using insulin glargine no statistically significant difference was observed.
Keywords : Diabetes mellitus type 2; Glargine insulin; NPH insulin; Hypoglycemia; Metabolic control.